Andrei M. Darie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrei M. Darie has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Michael Tamm
10 shared publicationsWerner Strobel
7 shared publicationsKathleen Jahn
6 shared publicationsLeticia Grize
6 shared publicationsMaria Pascarella
6 shared publicationsAnna Salina
5 shared publications
Latest Publications
- Open Access
- 8 January 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
ERS Congress 2025: highlights from the Thoracic Surgery and Lung Transplantation Assembly
The 2025 European Respiratory Society (ERS) Congress, held in Amsterdam, the Netherlands, from 27 September to 1 October, provided a dynamic forum for scientific exchange, fostering meaningful dialogue and showcasing significant advances in the field of respiratory medicine. Assembly 8 brings together physicians and surgeons with clinical expertise and research interests spanning cutting-edge developments in thoracic surgery (Group 8.01) and lung transplantation (Group 8.02). This article summarises the key highlights and contributions presented by both groups during the 2025 ERS Congress (figure 1).
- 8 January 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Open AccessERS Congress 2025: highlights from the Thoracic Surgery and Lung Transplantation Assembly
The 2025 European Respiratory Society (ERS) Congress, held in Amsterdam, the Netherlands, from 27 September to 1 October, provided a dynamic forum for scientific exchange, fostering meaningful dialogue and showcasing significant advances in the field of respiratory medicine. Assembly 8 brings together physicians and surgeons with clinical expertise and research interests spanning cutting-edge developments in thoracic surgery (Group 8.01) and lung transplantation (Group 8.02). This article summarises the key highlights and contributions presented by both groups during the 2025 ERS Congress (figure 1).
- 1 December 2025
- Published by S. Karger AG in Respiration
- Vol. 105 (5) , 627-632
High-Flow Oxygen Does Not Improve Oxygenation during Rigid Medical Thoracoscopy
Introduction: The sedation required for rigid medical thoracoscopy may be associated with hypoventilation and intermittent hypoxaemia. High-flow oxygen administration has been shown to decrease hypoxaemia during sedation for flexible bronchoscopy, a procedure using similar sedation protocols to medical thoracoscopy. Methods: An investigator-initiated randomised controlled trial to compare conventional oxygen (starting at 4 L/min) to high-flow nasal oxygen (starting rate 60 L/min and fraction of oxygen 0.6) during sedation for medical thoracoscopy. The mean nadir oxygen saturation (SpO2) during the procedure was the primary endpoint. Results: Between February 2022 and June 2023, 36 patients were randomised to either conventional oxygen (n = 20) or high-flow oxygen (n = 16). The majority of participants (20/36, 55.6%) were male, and the mean age was 75.4 ± 10.4 years. The nadir SpO2 was 88.3% using high flow as compared to 85.0% for conventional oxygen (p = 0.20). The average SpO2 (96.3% vs. 96.2%, p = 0.81) was similar between groups. There was a tendency towards a higher peak PtcCO2 in the conventional oxygen group (49.6 mm Hg vs. 55.5 mm Hg, p = 0.13). Conclusion: Oxygen supplementation using nasal high flow provides similar SpO2 to conventional nasal oxygen during sedation for rigid medical thoracoscopy.
- 1 December 2025
- Published by S. Karger AG in Respiration
- Vol. 105 (5) , 627-632
High-Flow Oxygen Does Not Improve Oxygenation during Rigid Medical Thoracoscopy
Introduction: The sedation required for rigid medical thoracoscopy may be associated with hypoventilation and intermittent hypoxaemia. High-flow oxygen administration has been shown to decrease hypoxaemia during sedation for flexible bronchoscopy, a procedure using similar sedation protocols to medical thoracoscopy. Methods: An investigator-initiated randomised controlled trial to compare conventional oxygen (starting at 4 L/min) to high-flow nasal oxygen (starting rate 60 L/min and fraction of oxygen 0.6) during sedation for medical thoracoscopy. The mean nadir oxygen saturation (SpO2) during the procedure was the primary endpoint. Results: Between February 2022 and June 2023, 36 patients were randomised to either conventional oxygen (n = 20) or high-flow oxygen (n = 16). The majority of participants (20/36, 55.6%) were male, and the mean age was 75.4 ± 10.4 years. The nadir SpO2 was 88.3% using high flow as compared to 85.0% for conventional oxygen (p = 0.20). The average SpO2 (96.3% vs. 96.2%, p = 0.81) was similar between groups. There was a tendency towards a higher peak PtcCO2 in the conventional oxygen group (49.6 mm Hg vs. 55.5 mm Hg, p = 0.13). Conclusion: Oxygen supplementation using nasal high flow provides similar SpO2 to conventional nasal oxygen during sedation for rigid medical thoracoscopy.
- 10 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 253-259
Lung transplantation for chronic thromboembolic pulmonary hypertension—a case series
- 10 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 253-259
Lung transplantation for chronic thromboembolic pulmonary hypertension—a case series
- 24 July 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (1) , 2500834
Reply to: The risk of hypoventilation during bronchoscopy under oxygen and procedural sedation
- 24 July 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (1) , 2500834
Reply to: The risk of hypoventilation during bronchoscopy under oxygen and procedural sedation
- 23 June 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 138, 46-47
Community-acquired pneumonia: The burden echoes well beyond discharge
- 23 June 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 138, 46-47
Community-acquired pneumonia: The burden echoes well beyond discharge
- 21 March 2025
- Published by S. Karger AG in Respiration
- Vol. 104 (8) , 575-585
Pulmonary Hypertension Associated with Interstitial Lung Disease: A Review on Diagnosis and Treatment with a Focus on Emerging Therapies
Background: Pulmonary hypertension (PH) complicating interstitial lung diseases (ILDs) is critical for symptom burden and prognosis. The prevalence of PH varies according to ILD subgroups and severities. Establishing the diagnosis of PH associated with ILDs (PH-ILDs) is complex due to overlapping symptoms, late clinical signs, and poor diagnostic performance of routine noninvasive diagnostic methods. Summary: Treatment options for PH-ILDs are limited and target mainly the underlying parenchymal lung disease. For decades, clinical trials of PH-ILD treatment using pulmonary vasodilators have failed showing no benefits or even harm. Thus, most PH-specific therapies are contra-indicated in PH-ILDs. Recently, the landmark INCREASE trial showed that inhaled treprostinil improved exercise capacity (6-min walking distance) and NT-proBNP, stabilized forced vital capacity, and reduced clinical worsening. Inhaled treprostinil was approved by the FDA in 2021, while approval in Europe and Switzerland is pending. Key Message: After its approval in Europe and Switzerland, the optimal use of inhaled treprostinil will require a careful patient selection with comprehensive assessments (including right heart catheterization) by highly specialized expert centers treating patients with both PH and ILDs.
- 21 March 2025
- Published by S. Karger AG in Respiration
- Vol. 104 (8) , 575-585
Pulmonary Hypertension Associated with Interstitial Lung Disease: A Review on Diagnosis and Treatment with a Focus on Emerging Therapies
Background: Pulmonary hypertension (PH) complicating interstitial lung diseases (ILDs) is critical for symptom burden and prognosis. The prevalence of PH varies according to ILD subgroups and severities. Establishing the diagnosis of PH associated with ILDs (PH-ILDs) is complex due to overlapping symptoms, late clinical signs, and poor diagnostic performance of routine noninvasive diagnostic methods. Summary: Treatment options for PH-ILDs are limited and target mainly the underlying parenchymal lung disease. For decades, clinical trials of PH-ILD treatment using pulmonary vasodilators have failed showing no benefits or even harm. Thus, most PH-specific therapies are contra-indicated in PH-ILDs. Recently, the landmark INCREASE trial showed that inhaled treprostinil improved exercise capacity (6-min walking distance) and NT-proBNP, stabilized forced vital capacity, and reduced clinical worsening. Inhaled treprostinil was approved by the FDA in 2021, while approval in Europe and Switzerland is pending. Key Message: After its approval in Europe and Switzerland, the optimal use of inhaled treprostinil will require a careful patient selection with comprehensive assessments (including right heart catheterization) by highly specialized expert centers treating patients with both PH and ILDs.
- 13 February 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 65 (5) , 2401586
Preventing oxygen desaturation during bronchoscopy in COPD patients using high-flow oxygen versus standard management: the randomised controlled PROSA 2 trial
Background: Patients with COPD are at increased risk for developing additional respiratory comorbidities associated with smoking, and are thus prone to undergo flexible bronchoscopy. However, COPD patients have increased periprocedural complications risk and lower oxygen saturation during bronchoscopy. Methods: This was an investigator-initiated, single-centre, open-label randomised controlled trial designed to assess the benefits of high-flow nasal oxygen compared to conventional low-flow oxygen by nasal cannula during conscious sedation for bronchoscopy in patients with COPD. Low flow was supplied at a starting rate of 4 L·min−1 and gradually increased up to 12 L·min−1 to maintain peripheral oxygen saturation (S pO2 ) >90%. High flow delivered starting at a rate of 60 L·min−1 and an inspiratory oxygen fraction of 0.6 was increased up to 80 L·min−1 to preserve S pO2 >90%. The primary end-point was cumulative hypoxaemia time. Results: We randomised 600 COPD cases with a median (interquartile range (IQR)) age of 69.0 (62.0–76.0) years to either high flow (n=295) or low flow (n=305). The cumulative hypoxaemia time was 53% lower in the high-flow group (1.8% (95% CI 1.5–2.2%) versus 3.8% (95% CI 3.2–4.5%) of monitoring time; pS pO2 <90%) compared to 6.0 (3.0–10.0) in the low-flow group (p<0.001). The low-flow group had five-fold higher odds of experiencing hypoxaemia during bronchoscopy, (OR 5.1, 95% CI 3.2–8.2; p<0.001). Conclusion: High flow is feasible, decreases cumulative hypoxaemia time and reduces hypoxaemia events during bronchoscopy in patients with COPD but does not impact patient comfort.
- 13 February 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 65 (5) , 2401586
Preventing oxygen desaturation during bronchoscopy in COPD patients using high-flow oxygen versus standard management: the randomised controlled PROSA 2 trial
Background: Patients with COPD are at increased risk for developing additional respiratory comorbidities associated with smoking, and are thus prone to undergo flexible bronchoscopy. However, COPD patients have increased periprocedural complications risk and lower oxygen saturation during bronchoscopy. Methods: This was an investigator-initiated, single-centre, open-label randomised controlled trial designed to assess the benefits of high-flow nasal oxygen compared to conventional low-flow oxygen by nasal cannula during conscious sedation for bronchoscopy in patients with COPD. Low flow was supplied at a starting rate of 4 L·min−1 and gradually increased up to 12 L·min−1 to maintain peripheral oxygen saturation (S pO2 ) >90%. High flow delivered starting at a rate of 60 L·min−1 and an inspiratory oxygen fraction of 0.6 was increased up to 80 L·min−1 to preserve S pO2 >90%. The primary end-point was cumulative hypoxaemia time. Results: We randomised 600 COPD cases with a median (interquartile range (IQR)) age of 69.0 (62.0–76.0) years to either high flow (n=295) or low flow (n=305). The cumulative hypoxaemia time was 53% lower in the high-flow group (1.8% (95% CI 1.5–2.2%) versus 3.8% (95% CI 3.2–4.5%) of monitoring time; pS pO2 <90%) compared to 6.0 (3.0–10.0) in the low-flow group (p<0.001). The low-flow group had five-fold higher odds of experiencing hypoxaemia during bronchoscopy, (OR 5.1, 95% CI 3.2–8.2; p<0.001). Conclusion: High flow is feasible, decreases cumulative hypoxaemia time and reduces hypoxaemia events during bronchoscopy in patients with COPD but does not impact patient comfort.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , OA4862
Molecular diagnostic resistance patterns in the BALF of hospitalised patients with pneumonia
Pneumonia is a leading cause of hospitalization and death in the general population. Currently, the identification of bacterial pathogens and resistance rely mainly on microbiological cultures. PCR-assays are emerging as a rapid, complementary method of detecting both bacteria and resistance genes in lower respiratory tract infections. This investigator-initiated, prospective, multicenter study explored the resistance patterns of bacteria detected in the brocho-alveolar lavage fluids (BALF). BALF from 208 hospitalized patients with pneumonia was assessed for antimicrobial resistance (AMR) using conventional microbiological culture and multiplex bacterial PCR (Curetis, Holzgerlingen, Germany), which detects the following resistance genes: ermB, mecA, mecC, tem, shv, ctx-M, imp, kpc, ndm, oxa-23, oxa-24, oxa-48, oxa-58, vim, sul1, gzrA83 and gyrA87. The patients’ mean age was 66 ± 14 years (65% males; 56% immunocompromised). Among 48 PCR-positive BALFs six also detected a resistance gene (12.5%) and 3/6 detected multiple resistance genes. The most prevalent resistance gene was tem (determinant of resistance to penicillins and early cephalosporins). Thirty-nine cultures identified a pathogenic bacterial agent, of which 16/39 (41%) identified an antibiotic resistance. Only four samples showed a matching resistance pattern of PCR and culture-based antibiotic susceptibility testing (Kappa coefficient for agreement was 0.40), suggesting poor concordance between the two testing methods (McNemar’s test, p=0.014). Molecular tests rarely detected resistance genes in a low resistance setting. The concordance with culture-based assays is low and requires further clinical validation.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , OA4862
Molecular diagnostic resistance patterns in the BALF of hospitalised patients with pneumonia
Pneumonia is a leading cause of hospitalization and death in the general population. Currently, the identification of bacterial pathogens and resistance rely mainly on microbiological cultures. PCR-assays are emerging as a rapid, complementary method of detecting both bacteria and resistance genes in lower respiratory tract infections. This investigator-initiated, prospective, multicenter study explored the resistance patterns of bacteria detected in the brocho-alveolar lavage fluids (BALF). BALF from 208 hospitalized patients with pneumonia was assessed for antimicrobial resistance (AMR) using conventional microbiological culture and multiplex bacterial PCR (Curetis, Holzgerlingen, Germany), which detects the following resistance genes: ermB, mecA, mecC, tem, shv, ctx-M, imp, kpc, ndm, oxa-23, oxa-24, oxa-48, oxa-58, vim, sul1, gzrA83 and gyrA87. The patients’ mean age was 66 ± 14 years (65% males; 56% immunocompromised). Among 48 PCR-positive BALFs six also detected a resistance gene (12.5%) and 3/6 detected multiple resistance genes. The most prevalent resistance gene was tem (determinant of resistance to penicillins and early cephalosporins). Thirty-nine cultures identified a pathogenic bacterial agent, of which 16/39 (41%) identified an antibiotic resistance. Only four samples showed a matching resistance pattern of PCR and culture-based antibiotic susceptibility testing (Kappa coefficient for agreement was 0.40), suggesting poor concordance between the two testing methods (McNemar’s test, p=0.014). Molecular tests rarely detected resistance genes in a low resistance setting. The concordance with culture-based assays is low and requires further clinical validation.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1786
High flow oxygen vs standard management during medical thoracoscopy - a randomised controlled trial
Introduction: Medical thoracoscopy is a complementary diagnostic and therapeutic procedure of pleural disease using similar sedation protocols as bronchoscopy. Correspondingly, thoracoscopy performed under sedation is associated with significant hypoventilation. High flow nasal oxygen (HFNO) has been shown to have positive effects for patients after extubation following surgical thoracoscopy. Aim: This study investigates whether HFNO improved oxygenation in patients undergoing medical thoracoscopy. Methods: In this investigator initiated, prospective, randomised controlled trial consecutive patients undergoing medical thoracoscopy were randomised to either 4 l/min conventional supplemental oxygen by nasal cannula or oxygen supplied using LM Flow 100 (Löwenstein Medical GmbH, Bad Ems, Germany) starting at a rate of 60 l/min and fraction of oxygen of 0.6. The primary endpoint is the mean lowest oxygen saturation during medical thoracoscopy. Results: The majority of the 27 randomised patients (14:13) included in the interim analysis were male (63%) and had a mean age of 73 ± 12 years. We observed that the lowest oxygen saturation was similar between groups (86% vs 85%, p=0.8). Moreover, there was no difference in the mean oxygen saturation during the procedure between groups (96% vs 96%, p=0.6). Additionally, the transcutaneous measured carbon dioxide levels did not differ between groups (42 vs 46 mmHg, p=0.2). Conclusion: Oxygen supplementation using HFNO during medical thoracoscopy does not improve oxygen saturation compared to conventional supplemental oxygen by nasal cannula.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1786
High flow oxygen vs standard management during medical thoracoscopy - a randomised controlled trial
Introduction: Medical thoracoscopy is a complementary diagnostic and therapeutic procedure of pleural disease using similar sedation protocols as bronchoscopy. Correspondingly, thoracoscopy performed under sedation is associated with significant hypoventilation. High flow nasal oxygen (HFNO) has been shown to have positive effects for patients after extubation following surgical thoracoscopy. Aim: This study investigates whether HFNO improved oxygenation in patients undergoing medical thoracoscopy. Methods: In this investigator initiated, prospective, randomised controlled trial consecutive patients undergoing medical thoracoscopy were randomised to either 4 l/min conventional supplemental oxygen by nasal cannula or oxygen supplied using LM Flow 100 (Löwenstein Medical GmbH, Bad Ems, Germany) starting at a rate of 60 l/min and fraction of oxygen of 0.6. The primary endpoint is the mean lowest oxygen saturation during medical thoracoscopy. Results: The majority of the 27 randomised patients (14:13) included in the interim analysis were male (63%) and had a mean age of 73 ± 12 years. We observed that the lowest oxygen saturation was similar between groups (86% vs 85%, p=0.8). Moreover, there was no difference in the mean oxygen saturation during the procedure between groups (96% vs 96%, p=0.6). Additionally, the transcutaneous measured carbon dioxide levels did not differ between groups (42 vs 46 mmHg, p=0.2). Conclusion: Oxygen supplementation using HFNO during medical thoracoscopy does not improve oxygen saturation compared to conventional supplemental oxygen by nasal cannula.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA5227
High flow oxygen vs standard management during bronchoscopy in COPD patients – a randomised controlled trial
Patients with COPD/emphysema are at increased risk to develop malignancy and pulmonary infections and therefore frequently undergo diagnostic or therapeutic bronchoscopy. In addition, different interventional procedures such as valve/coil implantation or bronchial rheoplasty have been introduced. However, patients with COPD tend to have a lower mean and nadir transcutaneous oxygen saturation during bronchoscopy. This investigator initiated, prospective, randomized controlled trial evaluates whether oxygen delivery using high flow nasal oxygen (HFNO) during sedation for bronchoscopy will improve oxygenation in patients with COPD compared to conventional oxygen by nasal cannula. 600 patients with COPD undergoing bronchoscopy will be randomised to either supplemental oxygen at 4 l/min or oxygen supplied using LM Flow 100 starting at a flow rate of 60 l/min and fraction of oxygen of 0.6. The primary end point is hypoxemia time (oxygen saturation<90%) during bronchoscopy. The interim analysis included 399 patients with COPD, predominantly male (65%), with a mean age and BMI of 69±9 years and 25±5kg/m2 respectively. Hypoxemia time during bronchoscopy was significantly lower in the HFNO group (6.3%vs8.6%,p<0.0001). Additionally, the minimal measured oxygen saturation was lower in the control group (85%vs82%,p<0.0001). There was no difference between groups in both the average and highest value of transcutaneous measured carbon dioxide (44vs43mmHg,p0.27;54vs53,p=0.46). Oxygen delivery, and thus oxygen saturation during bronchoscopy is superior using HFNO compared to conventional supplemental oxygen by nasal cannula. HFNO should be considered during bronchoscopy in COPD patients.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA5227
High flow oxygen vs standard management during bronchoscopy in COPD patients – a randomised controlled trial
Patients with COPD/emphysema are at increased risk to develop malignancy and pulmonary infections and therefore frequently undergo diagnostic or therapeutic bronchoscopy. In addition, different interventional procedures such as valve/coil implantation or bronchial rheoplasty have been introduced. However, patients with COPD tend to have a lower mean and nadir transcutaneous oxygen saturation during bronchoscopy. This investigator initiated, prospective, randomized controlled trial evaluates whether oxygen delivery using high flow nasal oxygen (HFNO) during sedation for bronchoscopy will improve oxygenation in patients with COPD compared to conventional oxygen by nasal cannula. 600 patients with COPD undergoing bronchoscopy will be randomised to either supplemental oxygen at 4 l/min or oxygen supplied using LM Flow 100 starting at a flow rate of 60 l/min and fraction of oxygen of 0.6. The primary end point is hypoxemia time (oxygen saturation<90%) during bronchoscopy. The interim analysis included 399 patients with COPD, predominantly male (65%), with a mean age and BMI of 69±9 years and 25±5kg/m2 respectively. Hypoxemia time during bronchoscopy was significantly lower in the HFNO group (6.3%vs8.6%,p<0.0001). Additionally, the minimal measured oxygen saturation was lower in the control group (85%vs82%,p<0.0001). There was no difference between groups in both the average and highest value of transcutaneous measured carbon dioxide (44vs43mmHg,p0.27;54vs53,p=0.46). Oxygen delivery, and thus oxygen saturation during bronchoscopy is superior using HFNO compared to conventional supplemental oxygen by nasal cannula. HFNO should be considered during bronchoscopy in COPD patients.